DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.

The incorporation of radiotherapy into multimodality treatment plans has led to significant improvements in glioma patient survival. However, local recurrence from glioma resistance to ionizing radiation remains a therapeutic challenge. The tumoricidal effect of radiation therapy is largely attributed to the induction of dsDNA breaks (DSBs). In the past decade, there have been tremendous strides in understanding the molecular mechanisms underlying DSB repair. The identification of gene products required for DSB repair has provided novel therapeutic targets. Recent studies revealed that many US FDA-approved cancer agents inhibit DSB repair by interacting with repair proteins. This article will aim to provide discussion of DSB repair mechanisms to provide molecular targets for radiation sensitization of gliomas and a discussion of FDA-approved cancer therapies that modulate DSB repair to highlight opportunities for combination therapy with radiotherapy for glioma therapy.

[1]  Susan Meyer Goldstein,et al.  Ten years after: Interference of hospital slack in process performance benefits of quality practices , 2012 .

[2]  M. Labussière,et al.  Radiosensitizing properties of bortezomib depend on therapeutic schedule. , 2011, International journal of radiation oncology, biology, physics.

[3]  D. Hochhauser,et al.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. , 2011, Cancer research.

[4]  R. Bristow,et al.  Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. , 2010, Seminars in radiation oncology.

[5]  L. Chin,et al.  Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy , 2010, PloS one.

[6]  Jiandong Chen,et al.  Mechanism of p53 stabilization by ATM after DNA damage , 2010, Cell cycle.

[7]  N. Mailand,et al.  HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes , 2010, Nature Cell Biology.

[8]  S. Toms,et al.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.

[9]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[10]  Ralph Scully,et al.  Mechanisms of double-strand break repair in somatic mammalian cells. , 2009, The Biochemical journal.

[11]  J. Lam-mcculloch,et al.  Saddle block analgesia for high-dose-rate brachytherapy: A prospective study. , 2009, Brachytherapy.

[12]  J. Parvin,et al.  Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.

[13]  D. Ferguson,et al.  Multiple functions of MRN in end-joining pathways during isotype class switching , 2009, Nature Structural &Molecular Biology.

[14]  W. Curran,et al.  Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. , 2009, International journal of radiation oncology, biology, physics.

[15]  Bruce Mickey,et al.  EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. , 2009, Cancer research.

[16]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[17]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[18]  J. Ellenberg,et al.  RNF168 Binds and Amplifies Ubiquitin Conjugates on Damaged Chromosomes to Allow Accumulation of Repair Proteins , 2009, Cell.

[19]  Susan M. Chang,et al.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Camphausen,et al.  In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 , 2009, Clinical Cancer Research.

[21]  A. D’Andrea,et al.  Of Escherichia coli and Man: Understanding Glioma Resistance to Temozolomide Therapy , 2009 .

[22]  S. Kesari,et al.  A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. , 2009, Clinical neurosurgery.

[23]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Chalmers,et al.  Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. , 2008, International journal of radiation oncology, biology, physics.

[25]  Hong Wang,et al.  Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. , 2008, Cancer research.

[26]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[27]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[28]  A. Robles,et al.  HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair , 2008, Molecular Cancer Therapeutics.

[29]  S. Jackson,et al.  Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage , 2008, EMBO reports.

[30]  K. Camphausen,et al.  In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide , 2008, Clinical Cancer Research.

[31]  M. Ljungman,et al.  Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin , 2008, Molecular Cancer.

[32]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[33]  Michael B. Yaffe,et al.  RNF8 Transduces the DNA-Damage Signal via Histone Ubiquitylation and Checkpoint Protein Assembly , 2007, Cell.

[34]  Jiri Bartek,et al.  Human CtIP promotes DNA end resection , 2007, Nature.

[35]  M. Mehta,et al.  Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. , 2007, Clinical advances in hematology & oncology : H&O.

[36]  H. Kimura,et al.  Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. , 2007, Cancer research.

[37]  K. Camphausen,et al.  Inhibition of Hsp90: A Multitarget Approach to Radiosensitization , 2007, Clinical Cancer Research.

[38]  Junjie Chen,et al.  Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response , 2007, Science.

[39]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[40]  P. Dent,et al.  Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. , 2007, Cancer research.

[41]  R. Kanaar,et al.  DNA double-strand break repair: all's well that ends well. , 2006, Annual review of genetics.

[42]  K. Camphausen,et al.  Inhibition of hsp90 compromises the DNA damage response to radiation. , 2006, Cancer research.

[43]  K. Aldape,et al.  Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.

[44]  D. Wazer,et al.  DSS1 is required for the stability of BRCA2 , 2006, Oncogene.

[45]  David N Louis,et al.  Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.

[46]  F. Alt,et al.  MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. , 2006, Molecular cell.

[47]  M. Yaffe,et al.  MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks , 2005, Cell.

[48]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[49]  V. Macaulay,et al.  EGFR Mutations and Lung Cancer , 2005, PLoS Medicine.

[50]  Haico van Attikum,et al.  The histone code at DNA breaks: a guide to repair? , 2005, Nature Reviews Molecular Cell Biology.

[51]  David J. Chen,et al.  Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.

[52]  S. West,et al.  BRCA2 BRC motifs bind RAD51-DNA filaments. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[54]  Ji-Hoon Lee,et al.  ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex , 2005, Science.

[55]  T. Paull,et al.  The Mre11/Rad50/Nbs1 Complex and Its Role as a DNA Double-Strand Break Sensor for ATM , 2005, Cell cycle.

[56]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[57]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  G. Cagney,et al.  Proteasome involvement in the repair of DNA double-strand breaks. , 2004, Molecular cell.

[59]  A. Ashworth,et al.  DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells , 2004, EMBO reports.

[60]  A. Venkitaraman,et al.  DNA recombination, chromosomal stability and carcinogenesis: insights into the role of BRCA2. , 2004, DNA repair.

[61]  J. Tainer,et al.  Structure and function of the double-strand break repair machinery. , 2004, DNA repair.

[62]  S. Ferrari,et al.  Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. , 2004, Genes & development.

[63]  S. West,et al.  RAD51C Is Required for Holliday Junction Processing in Mammalian Cells , 2004, Science.

[64]  R. Kanaar,et al.  Rad52 and Ku bind to different DNA structures produced early in double-strand break repair. , 2003, Nucleic acids research.

[65]  Yunmei Ma,et al.  Mechanism and regulation of human non-homologous DNA end-joining , 2003, Nature Reviews Molecular Cell Biology.

[66]  S. Powell,et al.  Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation , 2003, Oncogene.

[67]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[68]  Wen-Hwa Lee,et al.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. , 2002, Science.

[69]  T. Mak,et al.  Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Jackson,et al.  The MRE11 complex: at the crossroads of DNA repair and checkpoint signalling , 2002, Nature Reviews Molecular Cell Biology.

[71]  R. Abraham Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.

[72]  J. Walker,et al.  Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair , 2001, Nature.

[73]  S. Elledge,et al.  Direct DNA binding by Brca1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  J. Turchi,et al.  Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. , 2000, Nucleic acids research.

[75]  V. Yamazaki,et al.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.

[76]  D. Ramsden,et al.  Ku Recruits the XRCC4-Ligase IV Complex to DNA Ends , 2000, Molecular and Cellular Biology.

[77]  J. Harper,et al.  Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.

[78]  S. Jackson,et al.  DNA double-strand break repair , 1999, Current Biology.

[79]  K. Kinzler,et al.  14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.

[80]  M. Eijpe,et al.  Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis , 1999, Nature Genetics.

[81]  E. Rogakou,et al.  Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo , 1999, The Journal of cell biology.

[82]  A. Ashworth,et al.  Interaction between the Product of the Breast Cancer Susceptibility Gene BRCA2 and DSS1, a Protein Functionally Conserved from Yeast to Mammals , 1999, Molecular and Cellular Biology.

[83]  V. Ferrans,et al.  Ras Proteins Induce Senescence by Altering the Intracellular Levels of Reactive Oxygen Species* , 1999, The Journal of Biological Chemistry.

[84]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[85]  Y. Yamaguchi-Iwai,et al.  Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells , 1998, The EMBO journal.

[86]  J. Haber,et al.  Saccharomyces Ku70, Mre11/Rad50, and RPA Proteins Regulate Adaptation to G2/M Arrest after DNA Damage , 1998, Cell.

[87]  T. Lindahl,et al.  A newly identified DNA ligase of Saccharomyces cerevisiae involved in RAD52-independent repair of DNA double-strand breaks. , 1997, Genes & development.

[88]  M. Resnick,et al.  A double-strand break within a yeast artificial chromosome (YAC) containing human DNA can result in YAC loss, deletion or cell lethality , 1996, Molecular and cellular biology.

[89]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[90]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[91]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[92]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[93]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[94]  A. Giaccia,et al.  The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Virginia A. Zakian,et al.  Loss of a yeast telomere: Arrest, recovery, and chromosome loss , 1993, Cell.

[96]  M. Resnick,et al.  Lethality induced by a single site-specific double-strand break in a dispensable yeast plasmid. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[97]  S. Jackson,et al.  The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen , 1993, Cell.

[98]  N. Bleehen,et al.  A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.

[99]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[100]  M. Walker,et al.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.

[101]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[102]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[103]  E. Gehan,et al.  Evaluation of mithramycin in the treatment of anaplastic gliomas. , 1976, Journal of neurosurgery.

[104]  C. J. Gillespie,et al.  DNA strand breaks, repair, and survival in x-irradiated mammalian cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[105]  R. Mortimer,et al.  A genetic study of x-ray sensitive mutants in yeast. , 1974, Mutation research.